Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer

JAMA

Volumn 298, Issue 19, 2007, Pages 2275-2280

  Bañez, Lionel L ^a,b   Hamilton, Robert J ^a,b,c   Partin, Alan W ^d   Vollmer, Robin T ^a,b   Sun, Leon ^a   Rodriguez, Carmen ^e   Wang, Yiting ^e   Terris, Martha K ^f,g   Aronson, William J ^h   Presti, Joseph C ⁱ   Kane, Christopher J ^j,k   Amling, Christopher L ^l   Moul, Judd W ^a   Freedland, Stephen J ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e AMERICAN CANCER SOCIETY   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g MEDICAL COLLEGE OF GEORGIA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l Alabama   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; DATA BASE; HEMODILUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PLASMA VOLUME; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY;

EID: 36348982774     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.19.2275     Document Type: Article

References (37)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288(14):1723-1727.
2. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625-1638.
3. Bray GA. The underlying basis for obesity: relationship to cancer. J Nutr. 2002;132(11)(suppl):3451S-3455S.
4. Bray GA. Obesity: the disease. J Med Chem. 2006;49(14):4001-4007.
5. Freedland SJ, Platz EA, Presti JC Jr, et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol. 2006;175(2):500-504.
6. Baillargeon J, Pollock BH, Kristal AR, et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer. 2005;103(5):1092-1095.
7. Barqawi AB, Golden BK, O'Donnell C, Brawer MK, Crawford ED. Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology. 2005;65(4):708-712.
8. Gray MA, Delahunt B, Fowles JR, Weinstein P, Cookes RR, Nacey JN. Demographic and clinical factors as determinants of serum levels of prostate specific antigen and its derivatives. Anticancer Res. 2004;24(3b):2069-2072.
9. Ku JH, Kim ME, Lee NK, Park YH, Ahn JO. Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men. Urology. 2003;61(1):132-136.
10. Werny DM, Thompson T, Saraiya M, et al. Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev. 2007;16(1):70-76.
11. Fowke JH, Signorello LB, Chang SS, et al. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer. 2006;107 (10):2361-2367.
12. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev. 2001;10(4):345-353.
13. Vollmer RT, Humphrey PA. Tumor volume in prostate cancer and serum prostate-specific antigen: analysis from a kinetic viewpoint. Am J Clin Pathol. 2003;119(1):80-89.
14. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17(6):863-871.
15. Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol. 1984;247(4, pt 2):F632-F636.
16. Physical status: the use and interpretation of anthropometry: report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854:1-452.
17. Das UN. Is obesity an inflammatory condition? Nutrition. 2001;17(11-12):953-966.
18. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579-591.
19. Purohit A, Reed MJ. Regulation of estrogen synthesis in postmenopausal women. Steroids. 2002;67(12):979-983.
20. Nyholm HC, Nielsen AL, Lyndrup J, Dreisler A, Hagen C, Haug E. Plasma oestrogens in postmenopausal women with endometrial cancer. Br J Obstet Gynaecol. 1993;100(12):1115-1119.
21. Wolff JM, Ting O, Borchers H, Rohde D, Jakse G. Serum levels of prostate specific antigen in men on hemodialysis. Anticancer Res. 2000;20(6D):5191-5193.
22. Tzanakis I, Kazoulis S, Girousis N, et al. Prostate-specific antigen in hemodialysis patients and the influence of dialysis in its levels. Nephron. 2002;90 (2):230-233.
23. Schwartz LM, Woloshin S, Fowler FJ Jr, Welch HG. Enthusiasm for cancer screening in the United States. JAMA. 2004;291(1):71-78.
24. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA. 2003;289(11):1414-1420.
25. Amling CL, Riffenburgh RH, Sun L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004;22(3):439-445.
26. Bassett WW, Cooperberg MR, Sadetsky N, et al. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology. 2005;66(5):1060-1065.
27. Giovannucci E, Rimm EB, Liu Y, et al. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst. 2003;95(16):1240-1244.
28. Rodriguez C, Freedland SJ, Deka A, et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2007;16(1):63-69.
29. Wright ME, Chang SC, Schatzkin A, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer. 2007;109(4):675-684.
30. Porter MP, Stanford JL. Obesity and the risk of prostate cancer. Prostate. 2005;62(4):316-321.
31. Freedland SJ, Grubb KA, Yiu SK, et al. Obesity and capsular incision at the time of open retropubic radical prostatectomy. J Urol. 2005;174(5):1798-1801.
32. Freedland SJ, Aronson WJ, Kane CJ, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol. 2004;22(3):446-453.
33. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351(2):125-135.
34. Hakim R. Handbook of Dialysis. 2nd ed. Boston, MA: Little Brown & Co; 1994.
35. Moul JW, Sesterhenn IA, Connelly RR, et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA. 1995;274(16):1277-1281.
36. Henderson RJ, Eastham JA, Culkin DJ, et al. Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer. J Natl Cancer Inst. 1997;89(2):134-138.
37. Mavropoulos JC, Partin AW, Amling CL, et al. Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men? Urology. 2007;69(6):1138-1142.